Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-29	SEK 3.500	+1.74%	299,588
26-10-28	SEK 3.440	+0.88%	85,768
26-10-27	SEK 3.410	-1.16%	102,688
26-10-26	SEK 3.450	+3.29%	228,429
26-10-23	SEK 3.340	-0.30%	49,508

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Sprint Bioscience AB

Company calendar

Market Closed - Nasdaq Stockholm 01:00:00 2026-10-29 pm EDT			5-day change	1st Jan Change
3.500 ^SEK	+1.74%		+4.48%	+138.10%

Aug. 26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	363M 36.82M 32.98M 30.42M 27.53M 51.48M 3.51B 52.31M 145M 1.83B 138M 135M 5.81B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	363M 36.82M 32.98M 30.42M 27.53M 51.48M 3.51B 52.31M 145M 1.83B 138M 135M 5.81B	EV / Sales 2026 *	4.18x	EV / Sales 2027 *	3.75x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

Aug. 26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
Jun. 26	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
Jun. 18	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
Jun. 16	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
Jun. 09	Calendar: Tuesday, June 9	FW
Jun. 08	Calendar Tuesday June 9	FW
May. 13	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
May. 13	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 16	Sprint Bioscience completes strategic evaluation of STK25 program	RE
Apr. 16	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
Apr. 14	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
Apr. 10	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Stock

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news: Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

Oct. 02	Sprint Bioscience: Vinnova funding for fragment screening project	AQ
Oct. 01	Sprint Bioscience Receives Funding from Vinnova	AQ
Sep. 02	Sprint Bioscience (Q2 review): Continued positive progress	AQ
Aug. 13	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
Jul. 23	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ

1 day	+1.74%
1 week	+4.48%
Current month	+2.94%
1 month	+6.06%
3 months	-5.91%
6 months	+8.70%
Current year	+138.10%

1 week	3.25	3.7
1 month	3.25	3.88
Current year	1.36	4.59
1 year	0.58	4.59
3 years	0.36	4.59
5 years	0.36	5.16
10 years	0.36	37.5

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	2023-09-30
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	2008-12-31
Jenni Björnulfson DFI	Director of Finance/CFO	55	2026-05-03

Director	Title	Age	Since
Svein Arild Mathisen BRD	Director/Board Member	70	2019-12-31
Björn Magnus Sjöstrand CHM	Chairman	58	2020-12-31
Fredrik Lehmann BRD	Director/Board Member	50	2018-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	+1.74%	+4.48%	+382.09%	+84.21%	36.6M
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	53.03B
IQVIA HOLDINGS INC.	-1.51%	-1.28%	+26.13%	+55.09%	45.99B
BEONE MEDICINES AG	-0.92%	-3.21%	+17.52%	+98.27%	42.45B
REVOLUTION MEDICINES, INC.	-0.25%	+0.32%	+224.53%	+926.10%	40.45B
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	24.23B
Average	-0.31%	+3.00%	+85.05%	+154.42%	39.26B
Weighted average by Cap.	-0.27%	+3.13%	+49.17%	+159.92%

	2026 *	2027 *
Net sales	86.8M 8.8M 7.89M 7.28M 6.58M 12.31M 838M 12.51M 34.63M 439M 33.04M 32.34M 1.39B	96.8M 9.82M 8.79M 8.11M 7.34M 13.73M 935M 13.95M 38.62M 489M 36.85M 36.06M 1.55B
Net income	-	-
Net Debt	-	-